What kind of drug does sorafenib belong to? Is it a targeted therapy drug?

Sorafenib is a classic targeted therapy drug that is a multi-target tyrosine kinase inhibitor (TKI). Its main mechanism is to achieve anti-cancer effects by inhibiting a variety of enzymes and signaling pathways related to tumor growth and angiogenesis. It was first approved for the treatment of advanced hepatocellular carcinoma and is the world's first targeted drug proven to be effective against liver cancer. Therefore, it is an important milestone in the field of tumor targeted therapy.

From a molecular mechanism perspective, sorafenib can simultaneously inhibit two key processes: tumor cell proliferation and tumor angiogenesis. It mainly acts on the RAFkinase in the RAF/MEK/ERK pathway. It can also inhibit VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived growth factor receptor) and other targets related to tumor angiogenesis. It is this multi-target inhibition feature that gives sorafenib its unique advantages in controlling tumor growth.

The indications for sorafenib include advanced hepatocellular carcinoma, advanced renal cell carcinoma, and radioactive iodine-refractory thyroid cancer. Its targeting mechanism makes it an effective alternative in patients for whom traditional chemotherapy is ineffective or poorly tolerated. Unlike chemotherapy drugs, sorafenib does not kill normal cells in a large area, but controls the disease by interfering with the tumor growth path. Therefore, the side effects are relatively controllable, but you still need to be wary of common adverse reactions such as skin toxicity, diarrhea, and hypertension.

In summary, sorafenib is undoubtedly a targeted drug that achieves anti-tumor effects by simultaneously inhibiting the activities of multiple key tyrosine kinases. Although its status has declined slightly with the emergence of a new generation of targeted drugs, it is still widely used in the treatment of multiple solid tumors such as liver cancer, and is especially suitable for some patients for whom traditional treatments are ineffective. During the period of using sorafenib, patients should take the medication under the guidance of a professional doctor, and regularly monitor the efficacy and side effects to achieve the best therapeutic effect.

Reference materials:https://www.drugs.com